Communicators

-          Initial neuenergy® order shipped to and received in Germany

Vancouver, British Columbia – July 25, 2022 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTC PINK: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that its European distribution partner, TH International Consulting GmbH (“THIC”), has advised the Company that neuenergy® will be available for online purchase throughout Europe via www.getneuenergy.de starting today.

At first, the focus is primarily the German market. Roll-out for other European countries will follow in due course. neuenergy® will also be offered in a subscription model for consumer convenience.

neuenergy® is a sublingual energy tablet that boosts concentration and mental clarity without the sugar, calories and subsequent crash, that typically comes with conventional energy products. neuenergy® contains a unique, patented combination of blueberries (pterostilbene) and natural caffeine.

The European sports nutrition market is expected to achieve US$15.12 billion by 2026. The sports nutrition market in Europe has witnessed healthy growth rates in the past few years and is expected to continue this trend in the future.

Yusuf Taze, Managing Director of THIC, said, "We are very excited to finally launch neuenergy in Europe. Initially, it is of paramount importance to promote the brand to consumers and make them aware of the fantastic benefits of neuenergy. We assembled a strong and experienced sales team to achieve this goal."

Glen Rehman, CEO of NeutriSci, said, “Our European distributor THIC, together with its partner Yumilu GmbH, will launch extensive promotional activities in social media to build our brand in the identified target groups. The team of Yumilu is very experienced in managing and leveraging strong brands in the food industry in the German market.”

The Company is also pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”), held in Vancouver, British Columbia on July 7, 2022.  All resolutions presented to shareholders were approved (see SEDAR filing of the Company’s Information Circular, dated June 2, 2022).  As a result, Davidson & Company, Chartered Professional Accountants, was re-appointed as auditor of the Company, the number of directors was set at four with the following nominees elected as directors: Glen Rehman, Jeff Durno, Dana Montenegro, and Anthony Hugens, and, the Company’s new Security Based Compensation Plan was approved.  The plan is subject to TSX Venture Exchange acceptance.  The following officers were re-appointed after the Meeting: Glen Rehman as President & CEO, and Rob Chisholm as CFO and Corporate Secretary.

*source: https://www.marketdataforecast.com/market-reports/europe-sports-nutrition-market

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit: www.neutrisci.com.

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.

Glen Rehman

CEO

Tel: (403) 264-6320

investors@neutrisci.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.